Complete resolution and reduction in urgency incontinence episodes

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction:

Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment diffe

Effect: improvement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction: